The Members were in favour of launching the contract
,
. It was outlined that Valneva proposed a different
technology and Members agreed it would be useful to have it in the portfolio.
- discussions with the company were over and the Steering Committee should
decided.
exploratory talks continued.
It was suggested that a strategic discussion should take place on how to handle future
vaccine candidates.
4. Discussion on national vaccination strategies and logistics
Member States exchanged on the starting point and schedule of the national vaccination
strategies.
The Commission and the Members agreed on the importance of unity amongst the
Member States and a coordinated approach regarding the implementation of the
vaccines strategies.
The importance of waiting for the formal EMA evaluation and the (conditional)
marketing authorisation was also underlined.
The Commission provided an update on the state of play on the Joint Procurement for
needles and syringes.
5. COVAX
The Commission provided an update on the state of play on the COVAX APAs.
.
Regarding donations, the importance of an early delivery was outlined.
The Members were reminded that a subgroup on vaccine donation, reporting to the
Steering Board, would be set up with a 1st meeting on Thursday, 10 December. Member
States were invited to nominate representatives in this subgroup.
The Commission also underlined that the Council Conclusions of the next EUCO would
probably contain a point on donations.